Neoadjuvant chemotherapy for osteosarcoma of the jaw (OSJ) remains controversial despite being a standardized treatment in osteosarcoma of the long bones. We present a case of a 22-year-old male with OSJ and performed a retrospective systemic review of previously published literatures of OSJ. We identified 27 articles: 7% recommended neoadjuvant chemotherapy, 22% recommended adjuvant chemotherapy, 19% recommended both neoadjuvant and adjuvant chemotherapy, 33% recommended against chemotherapy and 19% stated the role of chemotherapy is unknown. The lack of consensus regarding the use of chemotherapy in OSJ, despite its benefits, demonstrates the need to establish a standardized algorithm for OSJ.
*Department of Pediatrics, Children’s Hospital Los Angeles, Los Angeles, CA
†Department of Pediatric Hematology/Oncology, Department of Pediatrics, Rush University Medical Center, Chicago, IL
Informed consent has been properly documented.
The authors declare no conflict of interest.
Reprints: Paul M. Kent, MD, FAAP, Department of Pediatrics, Medical Director, Sarcoma Program, Rush University Medical Center, Department of Pediatrics, Division of Hematology and Oncology, 1725 West Harrison Street, Suite 710, Chicago, IL 60612-3824 (e-mail: Paul_Kent@Rush.edu).
Received May 14, 2018
Accepted August 16, 2018